Core Viewpoint - Fiserv (FI) shares have increased by 1.4% over the past month, closing at $165.74, with a potential upside of 31.6% based on Wall Street analysts' mean price target of $218.09 [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of 34 short-term price targets with a standard deviation of $31.63, indicating variability among analysts; the lowest estimate is $125.00 (24.6% decline), while the highest is $268.00 (61.7% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research [9] Group 2: Earnings Estimates and Market Sentiment - There is growing optimism among analysts regarding Fiserv's earnings prospects, supported by a consensus of higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.2%, with four estimates moving higher and no negative revisions [12] - Fiserv holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Group 1 - Enliven Therapeutics, Inc. (ELVN) shares have increased by 8.2% over the past four weeks, closing at $23.34, with a mean price target of $41 indicating a potential upside of 75.7% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $6.74, where the lowest estimate of $33.00 suggests a 41.4% increase, and the highest estimate of $52.00 indicates a potential surge of 122.8% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as the Zacks Consensus Estimate for the current year has risen by 4.6% over the past month [11][12] Group 2 - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [13] - While consensus price targets may not be reliable indicators of the extent of gains, they can provide a directional guide for price movement [14]

Shares of Perrigo (PRGO) have gained 2.9% over the past four weeks to close the last trading session at $27.09, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $36.67 indicates a potential upside of 35.4%.The average comprises three short-term price targets ranging from a low of $30.00 to a high of $42.00, with a standard deviation of $6.11. While the lowest estimate indicates a ...

Group 1 - Ascendis Pharma A/S (ASND) shares have increased by 1.1% over the past four weeks, closing at $174.75, with a mean price target of $226.88 indicating a potential upside of 29.8% [1] - The mean estimate consists of 16 short-term price targets with a standard deviation of $28.42, where the lowest estimate is $194.00 (11% increase) and the highest is $289.00 (65.4% increase) [2] - Analysts show strong agreement on ASND's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for ASND's current year has increased by 2% over the past month, with no negative revisions [12] - ASND holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Group 1 - TeraWulf Inc. (WULF) shares have increased by 18% over the past four weeks, closing at $5.11, with a mean price target of $7.32 indicating a potential upside of 43.3% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $1.72, where the lowest estimate is $4.00 (21.7% decline) and the highest is $10.00 (95.7% increase) [2] - Analysts show strong agreement on WULF's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - Recent revisions of earnings estimates for WULF have been positive, with two estimates moving higher in the last 30 days and the Zacks Consensus Estimate increasing by 4.9% [12] - WULF holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [14]

Group 1 - Harmony Biosciences Holdings, Inc. (HRMY) shares have increased by 5.5% over the past four weeks, closing at $34.71, with a mean price target of $49.7 indicating a potential upside of 43.2% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $11.66, where the lowest estimate is $31.00 (10.7% decline) and the highest is $70.00 (101.7% increase) [2] - Analysts show a consensus that HRMY will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for HRMY has increased by 0.2% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - HRMY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Ero Copper Corp. (ERO) shows potential for significant upside, with a mean price target of $19.52 indicating a 29.3% increase from the current price of $15.1 [1] Price Targets and Analyst Consensus - The average of 14 short-term price targets ranges from a low of $15.98 to a high of $25.00, with a standard deviation of $2.65, indicating variability in analyst estimates [2] - The lowest estimate suggests a 5.8% increase, while the highest points to a 65.6% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ERO's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2% over the past month, with two estimates increasing and one decreasing [12] - ERO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - Tango Therapeutics, Inc. (TNGX) closed at $5.93, with a 26.4% gain over the past four weeks, and a mean price target of $10.43 indicating a 75.9% upside potential [1] - The average of seven short-term price targets ranges from $8.00 to $13.00, with a standard deviation of $2.23, suggesting a potential increase of 34.9% to 119.2% from the current price [2] - Analysts show strong agreement on TNGX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TNGX's current year has increased by 1% over the past month, with one estimate going higher and no negative revisions [12] - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [14]

Group 1 - Metsera Inc. (MTSR) shares have increased by 6.8% over the past four weeks, closing at $35.32, with a mean price target of $55 indicating a potential upside of 55.7% [1] - The mean estimate includes three short-term price targets with a standard deviation of $14.8, where the lowest estimate is $38.00 (7.6% increase) and the highest is $65.00 (84% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has risen by 1.9% over the last 30 days, with one estimate moving higher and no negative revisions [12] - MTSR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Core Viewpoint - Kimbell Royalty (KRP) shares have increased by 3.9% recently, with a mean price target of $18.6 suggesting a potential upside of 30.7% from the current price of $14.23 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $4.98, indicating variability among analysts [2] - The lowest estimate is $12.00, suggesting a 15.7% decline, while the highest estimate is $24.00, indicating a potential increase of 68.7% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism regarding KRP's earnings, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the past 30 days, one estimate has increased, leading to a 34.4% rise in the Zacks Consensus Estimate for the current year [12] - KRP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of KRP's potential gains, the direction indicated by these targets appears to be a useful guide for investors [14]